Learn more about the Hormonal IUD Avibela™


As hormonal IUDs become more affordable and new quality-assured brands are introduced to the market, access to this method is rapidly expanding worldwide. This trend is illustrated clearly in the 2022 Family Planning Market Report, which found that total public sector market volumes for hormonal IUDs increased by 785% between 2020 and 2021. This webinar provides information on the quality-assured hormonal IUD called AVIBELA. It is being organized by the Reproductive Health Supplies Coalition (RHSC) ForoLAC and presented by AVIBELA manufacturer Impact RH360, a fully owned subsidiary of the not-for-profit pharmaceutical organization Medicines360.

You are currently offline. Some pages or content may fail to load.